Efficacy and safety of bamlanivimab in patients with COVID-19: A systematic review and meta-analysis

Table 2 Subgroup and sensitivity analyses for efficacy and safety outcomes

Analysis	Studies, n	Sample size, n	Point estimate (95%CI)	P value	Heterogeneity
					Q value	P value	I2
Sensitivity analysis
Mortality rate soc (excluding Brock 2021and Djuric 2021)	16	29091	0.52 (0.37-0.73)	< 0.001	18.45	0.24	18.71
Hospitalization rate (excluding Brock 2021)	17	26565	0.55 (0.42-0.71)	< 0.001	69.65	0.21	77.02
Hospitalization rate (excluding Voelker 2022)	7	8177	1.38 (1.00-1.92)	0.04	14.25	0.02	57.91
ICU admission (excluding Brock 2021)	6	15759	0.88 (0.60-1.29)	0.52	7.79	0.16	35.81
Subgroup analysis
Hospitalization rate by design, BAM vs SOC/PBO
OS	16	25904	0.67 (0.60-0.75)	< 0.001	82.27	< 0.001	81.76
RCT	2	769	0.44 (0.21-0.94)	0.03	1.95	0.16	48.80
Hospitalization rate by sample size, BAM vs SOC/PBO
< 1000	11	23453	0.51 (0.43-0.61)	< 0.001	50.51	< 0.001	80.20
≥ 1000	7	3220	0.77 (0.67-0.89)	< 0.001	22.22	0.001	73.00
Hospitalization rate by mean age, BAM vs SOC/PBO
< 65	8	22783	0.77 (0.67-0.88)	< 0.001	26.91	< 0.001	73.99
≥ 65	4	1918	0.46 (0.32-0.66)	< 0.001	0.30	0.96	< 0.001
Mortality rate by design, BAM vs SOC/PBO
OS	17	28916	0.44 (0.31-0.62)	< 0.001	14.67	0.54	0.00
RCT	1	314	1.67 (0.57-4.86)	0.34	0.00	1.00	0.00
Mortality rate by sample size, BAM vs SOC/PBO
< 1000	12	4030	0.48 (0.31-0.76)	0.002	15.55	0.15	29.29
≥ 1000	6	25200	0.51 (0.31-0.84)	0.009	4.43	0.48	0.00
Mortality rate by mean age, BAM vs SOC/PBO
< 65	8	25639	0.60 (0.37-0.96)	0.037	9.89	0.19	29.26
≥ 65	5	2189	0.40 (0.20-0.79)	0.008	5.16	0.27	22.53

CI: Confidence interval; ED: Emergency department; mAb: Monoclonal antibody; PBO: Placebo; RCT: Randomized clinical trial; OS: Observational study; SOC: Standard of care.